tiprankstipranks
Trending News
More News >
IDEAYA Biosciences (IDYA)
NASDAQ:IDYA
US Market
Advertisement

IDEAYA Biosciences (IDYA) Stock Forecast & Price Target

Compare
615 Followers
See the Price Targets and Ratings of:

IDYA Analyst Ratings

Strong Buy
17Ratings
Strong Buy
15 Buy
2 Hold
0 Sell
Based on 17 analysts giving stock ratings to
IDEAYA
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IDYA Stock 12 Month Forecast

Average Price Target

$48.40
▲(45.83% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for IDEAYA Biosciences in the last 3 months. The average price target is $48.40 with a high forecast of $79.00 and a low forecast of $30.00. The average price target represents a 45.83% change from the last price of $33.19.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","80":"$80","29.75":"$29.8","46.5":"$46.5","63.25":"$63.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$79.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,29.75,46.5,63.25,80],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.36,31.33230769230769,35.30461538461538,39.276923076923076,43.24923076923077,47.22153846153846,51.19384615384615,55.16615384615385,59.13846153846154,63.11076923076923,67.08307692307693,71.05538461538461,75.0276923076923,{"y":79,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.36,28.978461538461538,30.596923076923076,32.215384615384615,33.83384615384615,35.45230769230769,37.07076923076923,38.68923076923077,40.30769230769231,41.926153846153845,43.54461538461538,45.16307692307692,46.78153846153846,{"y":48.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.36,27.563076923076924,27.766153846153845,27.96923076923077,28.17230769230769,28.375384615384615,28.57846153846154,28.78153846153846,28.984615384615385,29.18769230769231,29.39076923076923,29.593846153846155,29.796923076923076,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.73,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.35,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.77,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.27,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$79.00Average Price Target$48.40Lowest Price Target$30.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on IDYA
LifeSci Capital
LifeSci Capital
$58$62
Buy
86.80%
Upside
Reiterated
10/27/25
IDEAYA Biosciences: Strong Clinical Data and Financial Position Justify Buy RatingMeeng, ZLAB presented via Plenary Session updated clinical data for DLL3 topo-ADC ZL-1310, which previously read out data at ASCO 2025 and Triple Meeng 2024. Headline figures across included 60% ORR (including 6% unconfirmed; limited visibility into their eligibility for confirmaon) among all 2L SCLC paents, as well as 53% ORR (7% unconfirmed) and 68% ORR (10% unconfirmed) among 2L paents treated at 1.2 mg/kg and 1.6 mg/kg, respecvely. ZL-1310 reported 5.4 months mPFS in all paents, as well as 5.6 months mPFS in 2L paents per the abstract. We'd also note ZL-1310's early efficacy in paents with prior DLL3-targeted therapy, which included 40% ORR among N=10 paents with prior DLL3 T-cell engager therapy - this is unsurprising to us and also validang for IDE849 (and other DLL3 topo-ADCs) with respect to retaining efficacy aer AMGN's tarlatamab.
UBS
$50
Buy
50.65%
Upside
Reiterated
10/24/25
UBS Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)
J.P. Morgan Analyst forecast on IDYA
J.P. Morgan
J.P. Morgan
$74$79
Buy
138.02%
Upside
Reiterated
10/23/25
Ideaya Biosciences price target raised to $79 from $74 at JPMorganIdeaya Biosciences price target raised to $79 from $74 at JPMorgan
Guggenheim Analyst forecast on IDYA
Guggenheim
Guggenheim
$50
Buy
50.65%
Upside
Reiterated
10/22/25
Guggenheim Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)
Leerink Partners Analyst forecast on IDYA
Leerink Partners
Leerink Partners
$30$33
Hold
-0.57%
Downside
Reiterated
10/21/25
Leerink Partners Reaffirms Their Hold Rating on IDEAYA Biosciences (IDYA)
Mizuho Securities Analyst forecast on IDYA
Mizuho Securities
Mizuho Securities
$44
Buy
32.57%
Upside
Reiterated
10/21/25
Mizuho Securities Remains a Buy on IDEAYA Biosciences (IDYA)Coming away with growing confidence in daro, we reiterate our OP rating on IDYA.
BTIG
$62
Buy
86.80%
Upside
Reiterated
10/21/25
Promising Potential of IDEAYA Biosciences' Darovasertib: Strong Efficacy and Safety in Uveal Melanoma Trials
Goldman Sachs Analyst forecast on IDYA
Goldman Sachs
Goldman Sachs
$27$30
Hold
-9.61%
Downside
Reiterated
10/21/25
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), IDEAYA Biosciences (NASDAQ: IDYA) and Rani Therapeutics Holdings (NASDAQ: RANI)
RBC Capital Analyst forecast on IDYA
RBC Capital
RBC Capital
$38$41
Buy
23.53%
Upside
Reiterated
10/20/25
Ideaya Biosciences price target raised to $41 from $38 at RBC CapitalIdeaya Biosciences price target raised to $41 from $38 at RBC Capital
TD Cowen
Buy
Reiterated
10/20/25
TD Cowen Remains a Buy on IDEAYA Biosciences (IDYA)We remain Buy rated.
Citi
$64
Buy
92.83%
Upside
Reiterated
10/19/25
IDEAYA Biosciences: Promising Phase 1/2 Trial Results and Strong Upside Potential Justify Buy RatingWe not only expect IDYA’s Ph3 MUM to deliver favorable PFS by YE25 (~7 months is reasonable based on Ph1/2, >2X tebe, with control around ~3 months) but the new Ph1/2 OS data also support positive Ph3 OS.
Citizens JMP Analyst forecast on IDYA
Citizens JMP
Citizens JMP
$45
Buy
35.58%
Upside
Reiterated
10/13/25
Citizens JMP Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $45.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
Wells Fargo
$44
Buy
32.57%
Upside
Reiterated
09/09/25
Ideaya should be bought on yesterday's selloff, says Wells FargoIdeaya should be bought on yesterday's selloff, says Wells Fargo
Cantor Fitzgerald Analyst forecast on IDYA
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
09/09/25
Cantor Fitzgerald Remains a Buy on IDEAYA Biosciences (IDYA)Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and {REMOVEPT} price target on Ideaya Biosciences (NASDAQ: IDYA).
Wedbush
$46
Buy
38.60%
Upside
Reiterated
09/08/25
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on IDYA
LifeSci Capital
LifeSci Capital
$58$62
Buy
86.80%
Upside
Reiterated
10/27/25
IDEAYA Biosciences: Strong Clinical Data and Financial Position Justify Buy RatingMeeng, ZLAB presented via Plenary Session updated clinical data for DLL3 topo-ADC ZL-1310, which previously read out data at ASCO 2025 and Triple Meeng 2024. Headline figures across included 60% ORR (including 6% unconfirmed; limited visibility into their eligibility for confirmaon) among all 2L SCLC paents, as well as 53% ORR (7% unconfirmed) and 68% ORR (10% unconfirmed) among 2L paents treated at 1.2 mg/kg and 1.6 mg/kg, respecvely. ZL-1310 reported 5.4 months mPFS in all paents, as well as 5.6 months mPFS in 2L paents per the abstract. We'd also note ZL-1310's early efficacy in paents with prior DLL3-targeted therapy, which included 40% ORR among N=10 paents with prior DLL3 T-cell engager therapy - this is unsurprising to us and also validang for IDE849 (and other DLL3 topo-ADCs) with respect to retaining efficacy aer AMGN's tarlatamab.
UBS
$50
Buy
50.65%
Upside
Reiterated
10/24/25
UBS Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)
J.P. Morgan Analyst forecast on IDYA
J.P. Morgan
J.P. Morgan
$74$79
Buy
138.02%
Upside
Reiterated
10/23/25
Ideaya Biosciences price target raised to $79 from $74 at JPMorganIdeaya Biosciences price target raised to $79 from $74 at JPMorgan
Guggenheim Analyst forecast on IDYA
Guggenheim
Guggenheim
$50
Buy
50.65%
Upside
Reiterated
10/22/25
Guggenheim Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)
Leerink Partners Analyst forecast on IDYA
Leerink Partners
Leerink Partners
$30$33
Hold
-0.57%
Downside
Reiterated
10/21/25
Leerink Partners Reaffirms Their Hold Rating on IDEAYA Biosciences (IDYA)
Mizuho Securities Analyst forecast on IDYA
Mizuho Securities
Mizuho Securities
$44
Buy
32.57%
Upside
Reiterated
10/21/25
Mizuho Securities Remains a Buy on IDEAYA Biosciences (IDYA)Coming away with growing confidence in daro, we reiterate our OP rating on IDYA.
BTIG
$62
Buy
86.80%
Upside
Reiterated
10/21/25
Promising Potential of IDEAYA Biosciences' Darovasertib: Strong Efficacy and Safety in Uveal Melanoma Trials
Goldman Sachs Analyst forecast on IDYA
Goldman Sachs
Goldman Sachs
$27$30
Hold
-9.61%
Downside
Reiterated
10/21/25
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), IDEAYA Biosciences (NASDAQ: IDYA) and Rani Therapeutics Holdings (NASDAQ: RANI)
RBC Capital Analyst forecast on IDYA
RBC Capital
RBC Capital
$38$41
Buy
23.53%
Upside
Reiterated
10/20/25
Ideaya Biosciences price target raised to $41 from $38 at RBC CapitalIdeaya Biosciences price target raised to $41 from $38 at RBC Capital
TD Cowen
Buy
Reiterated
10/20/25
TD Cowen Remains a Buy on IDEAYA Biosciences (IDYA)We remain Buy rated.
Citi
$64
Buy
92.83%
Upside
Reiterated
10/19/25
IDEAYA Biosciences: Promising Phase 1/2 Trial Results and Strong Upside Potential Justify Buy RatingWe not only expect IDYA’s Ph3 MUM to deliver favorable PFS by YE25 (~7 months is reasonable based on Ph1/2, >2X tebe, with control around ~3 months) but the new Ph1/2 OS data also support positive Ph3 OS.
Citizens JMP Analyst forecast on IDYA
Citizens JMP
Citizens JMP
$45
Buy
35.58%
Upside
Reiterated
10/13/25
Citizens JMP Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $45.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
Wells Fargo
$44
Buy
32.57%
Upside
Reiterated
09/09/25
Ideaya should be bought on yesterday's selloff, says Wells FargoIdeaya should be bought on yesterday's selloff, says Wells Fargo
Cantor Fitzgerald Analyst forecast on IDYA
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
09/09/25
Cantor Fitzgerald Remains a Buy on IDEAYA Biosciences (IDYA)Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and {REMOVEPT} price target on Ideaya Biosciences (NASDAQ: IDYA).
Wedbush
$46
Buy
38.60%
Upside
Reiterated
09/08/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering IDEAYA Biosciences

1 Month
xxx
Success Rate
10/16 ratings generated profit
63%
Average Return
+4.94%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +4.94% per trade.
3 Months
xxx
Success Rate
10/16 ratings generated profit
63%
Average Return
+13.81%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +13.81% per trade.
1 Year
Charles ZhuLifeSci Capital
Success Rate
15/21 ratings generated profit
71%
Average Return
+40.21%
reiterated a buy rating 4 days ago
Copying Charles Zhu's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +40.21% per trade.
2 Years
xxx
Success Rate
14/21 ratings generated profit
67%
Average Return
+40.24%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +40.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IDYA Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
15
10
6
25
27
Buy
0
2
4
8
8
Hold
7
11
10
15
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
23
20
48
42
In the current month, IDYA has received 35 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. IDYA average Analyst price target in the past 3 months is 48.40.
Each month's total comprises the sum of three months' worth of ratings.

IDYA Financial Forecast

IDYA Earnings Forecast

Next quarter’s earnings estimate for IDYA is -$0.83 with a range of -$0.95 to -$0.63. The previous quarter’s EPS was -$0.88. IDYA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year IDYA has Preformed in-line its overall industry.
Next quarter’s earnings estimate for IDYA is -$0.83 with a range of -$0.95 to -$0.63. The previous quarter’s EPS was -$0.88. IDYA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year IDYA has Preformed in-line its overall industry.

IDYA Sales Forecast

Next quarter’s sales forecast for IDYA is $6.34M with a range of $0.00 to $12.50M. The previous quarter’s sales results were $0.00. IDYA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year IDYA has Preformed in-line its overall industry.
Next quarter’s sales forecast for IDYA is $6.34M with a range of $0.00 to $12.50M. The previous quarter’s sales results were $0.00. IDYA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year IDYA has Preformed in-line its overall industry.

IDYA Stock Forecast FAQ

What is IDYA’s average 12-month price target, according to analysts?
Based on analyst ratings, IDEAYA Biosciences’s 12-month average price target is 48.40.
    What is IDYA’s upside potential, based on the analysts’ average price target?
    IDEAYA Biosciences has 45.83% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IDYA a Buy, Sell or Hold?
          IDEAYA Biosciences has a consensus rating of Strong Buy which is based on 15 buy ratings, 2 hold ratings and 0 sell ratings.
            What is IDEAYA Biosciences’s price target?
            The average price target for IDEAYA Biosciences is 48.40. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $79.00 ,the lowest forecast is $30.00. The average price target represents 45.83% Increase from the current price of $33.19.
              What do analysts say about IDEAYA Biosciences?
              IDEAYA Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of IDYA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis